
Lexeo Therapeutics, Inc.: updates and filings
Price
$2.96
November 20, 2026Market cap $245M
What Ploutos Investor adds for Lexeo Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2023
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 16, 2026next Feb 11, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
September 2026
August 2026
June 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 16, 2026Results of operations, Regulation FD disclosure, other material eventsForm8-K
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 4, 2026FilingFormEFFECT
- Oct 29, 2026Shelf registration for future offeringsFormS-3
- Oct 13, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Sep 29, 2026Acquisition or disposal of assets, unregistered sale of sharesForm8-K
- Sep 22, 2026Material agreement entered, other material eventsForm8-K
- Aug 14, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 12, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 12, 2026Results of operations, other material eventsForm8-K
- Aug 7, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 29, 2026Shareholder voteForm8-K
- Jun 15, 2026Regulation FD disclosure, other material eventsForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 16, 2026 | 8-K | Results of operations, Regulation FD disclosure, other material events | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 4, 2026 | EFFECT | Filing | Document |
| Oct 29, 2026 | S-3 | Shelf registration for future offerings | Document |
| Oct 13, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Sep 29, 2026 | 8-K | Acquisition or disposal of assets, unregistered sale of shares | Document |
| Sep 22, 2026 | 8-K | Material agreement entered, other material events | Document |
| Aug 14, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 12, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 12, 2026 | 8-K | Results of operations, other material events | Document |
| Aug 7, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 29, 2026 | 8-K | Shareholder vote | Document |
| Jun 15, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Feb 4, 2022.
The full analysis
What do Lexeo Therapeutics's filings show?
The filings are where every one of Lexeo Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.